Drug Safety Ends Ten Thousand Hons, Sticking to First Heart to Do Service, Safe Drug Use Month Launching Ceremony Held in Shizhen Pavilion
Release time:
2021-11-22
News from our newspaper In order to raise the public's awareness of safe drug use and enhance the public's understanding of drug supervision, on the morning of 11# April 12 , the launching ceremony of Jinhua City's "Safe Drug Use Month" in 2021 was held at the flagship store of Zhengfeng Pharmacy. Wu Weisheng, chairman of Jianfeng Pharmacy, took the stage as a representative of drug retail enterprises and promised to strictly control drug quality, for the masses of scientific and rational drug use escort.
Safe Medication Month is a key publicity activity held every year. Across the country, targeted publicity activities on the theme of safe medication are carried out on a variety of communication and exchange platforms, close to life, close to the grassroots, and close to the masses. This year's theme is "safe use of drugs, stick to the original intention". This activity in Jinhua City is carried out under the unified deployment and command of the Municipal Market Supervision Bureau and Wucheng District Branch. At the launching ceremony, through the establishment of explanation booths, distribution of materials, publicity panels, and rewards for expired drug recovery, the past people were explained in detail about drug safety, laws and regulations, and identification of counterfeit drugs. After the launching ceremony, a team of volunteers will be sent to the community to widely publicize and popularize drug safety laws and regulations and popular science knowledge, meet the needs of the people for safe drug use, improve the public's drug scientific literacy, and promote the social co governance of drug safety.
As a drug window directly facing the common people, Jianfeng Pharmacy solemnly stated that it will strictly implement relevant laws and regulations, strictly control drug quality, scientifically and rationally guide the masses to use drugs safely, and actively cooperate with the guidance of regulatory authorities and the supervision of all sectors of society. Contribute to the people's scientific and reasonable medication awareness and behavior habits, and create a good social atmosphere.
Jianfeng Pharmacy has always attached great importance to safe drug use and publicity, implemented the main responsibility of the enterprise in its daily work, and carried out long-term service items such as guidance on the use of drugs and medical devices for consumers, follow-up of drugs for customers, recovery of expired drugs, lectures on safe drug use knowledge, identification of traditional Chinese medicine, etc. During the publicity activities, stores such as Shizhen Pavilion will also "go out" and send teams to the community around the theme of the event to provide relevant services to the masses.
(ReporterChen Shengmu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page